Table 4.
Antimicrobial susceptibility patterns of bacteria isolated from urine samples
| Susceptibility | Bacterial Isolates | |||||||
|---|---|---|---|---|---|---|---|---|
| Antibiotics | Klebsiella | E. coli | Proteus | Pseudomonas | Citrobacter | S. aureus | Total | |
| AMP | S | 1 (1.9) | 2 (5.0) | 1 (14.3) | 0 (0.0) | 0 (0.0) | 3 (9.1) | 7 (5.0) |
| R | 51 (98.1) | 38 (95.0) | 6 (85.7) | 7 (100.0) | 1 (100.0) | 30 (90.1) | 133 (95.0) | |
| AMO | S | 2 (3.8) | 0 (0.0) | 2 (28.6) | 0 (0.0) | 0 (0.0) | 2 (6.1) | 6 (4.3) |
| R | 50 (96.2) | 40 (100.0) | 5 (71.4) | 7 (100.0) | 1 (100.0) | 31 (93.9) | 134 (95.7) | |
| AMOCLAV | S | 13 (25.0) | 13 (32.5) | 4 (57.1) | 1 (14.3) | 0 (0.0) | 7 (21.2) | 38 (27.1) |
| R | 39 (75.0) | 27 (67.5) | 3 (42.9) | 6 (85.7) | 1 (100.0) | 26 (78.8) | 102 (72.9) | |
| NITRO | S | 27 (51.9) | 32 (80.0) | 6 (85.7) | 0 (0.0) | 1 (100.0) | 27 (81.8) | 93 (66.4) |
| R | 25 (48.1) | 8 (20.0) | 1 (14.3) | 7 (100.0) | 0 (0.0) | 6 (18.2) | 47 (33.6) | |
| CAF | S | 34 (65.4) | 23 (57.5) | 3 (42.9) | 5 (71.4) | 0 (0.0) | 17 (51.5) | 82 (58.6) |
| R | 18 (34.6) | 17 (42.5) | 4 (57.1) | 2 (28.6) | 1 (100.0) | 16 (48.5) | 58 (41.4) | |
| CIPRO | S | 47 (90.4) | 31 (77.5) | 6 (85.7) | 3 (42.9) | 1 (100.0) | 22 (66.7) | 110 (78.6) |
| R | 5 (9.6) | 9 (22.5) | 1 (14.3) | 4 (57.1) | 0 (0.0) | 11 (33.3) | 30 (21.4) | |
| GENT | S | 47 (90.4) | 31 (77.5) | 6 (85.7) | 3 (42.9) | 1 (100.0) | 23 (69.7) | 111 (79.3) |
| R | 5 (9.6) | 9 (22.5) | 1 (14.3) | 4 (57.1) | 0 (0.0) | 10 (30.3) | 29 (20.7) | |
| CEFTCLAV | S | 31 (59.6) | 22 (55.0) | 4 (57.1) | 4 (57.1) | 0 (0.0) | 8 (24.2) | 69 (49.3) |
| R | 21 (40.4) | 18 (45.0) | 3 (42.9) | 3 (42.9) | 1 (100.0) | 25 (75.8) | 71 (50.7) | |
| CEFOTAX | S | 44 (84.6) | 38 (95.0) | 7 (100.0) | 6 (85.7) | 1 (100.0) | 18 (54.5) | 114 (81.4) |
| R | 8 (15.4) | 2 (5.0) | 0 (0.0) | 1 (14.3) | 0 (0.0) | 15 (45.5) | 26 (18.6) | |
| CEFUROX | S | 32 (61.5) | 28 (70.0) | 5 (71.4) | 4 (57.1) | 1 (100.0) | 22 (66.7) | 92 (65.7) |
| R | 20 (38.5) | 12 (30.0) | 2 (28.6) | 3 (42.9) | 0 (0.0) | 11 (33.3) | 48 (34.4) | |
| CEFTRI | S | 47 (90.4) | 33 (83.3) | 7 (100.0) | 7 (100.0) | 1 (100.0) | 21 (63.6) | 116 (82.9) |
| R | 5 (9.6) | 7 (16.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 12 (36.4) | 24 (17.4) | |
| IMIPEN | S | 50 (96.2) | 33 (83.3) | 5 (71.4) | 4 (57.1) | 1 (100.0) | 26 (78.8) | 119 (85.0) |
| R | 2 (3.8) | 7 (16.7) | 2 (28.6) | 3 (42.9) | 0 (0.0) | 7 (21.2) | 21 (15.0) | |
| ERYTH | S | 18 (54.5) | 18 (54.5) | |||||
| R | 15 (45.5) | 15 (45.5) | ||||||
| METH | S | 22 (66.7) | 22 (66.7) | |||||
| R | 11 (33.3) | 11 (33.3) | ||||||
AMP Ampicillin, AMO Amoxicillin, AMOCLAV Amoxicillin/Clavulanic acid, NITRO Nitrofurantoin, CAF Chloramphenicol, CIPRO Ciprofloxacin, GENT Gentamicin, CEFTCLAV Ceftazidime/Clavulanic acid, CEFOTAX Cefotaxime, CEFUROX Cefuroxime, CEFTRI Ceftriaxone, IMIPEN Imipenem, ERYTH Erythromycin, METH Methicillin, S. aureus Staphylococcus aureus, E. coli Escherichia coli, S Sensitive, R Resistant